Head-to-head evidence
eloralintide vs RM-718
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: Amylin receptor · full Obesity pipeline
eloralintide
Developed by Eli Lilly
NCT06230523 · Phase 2 · completed
Randomized, double-blind, placebo-controlled phase 2 in obesity and overweight (263 participants). Week-48 body-weight reductions ranged from 9.4% to 20.1% across eloralintide doses versus 0.4% on placebo, a separation many times larger than the reported error margins; percent change in body weight is the accepted registrational endpoint in obesity.
Next expected readout: December 2026 · NCT07738614 (registry estimate)
RM-718
Developed by Rhythm Pharmaceuticals
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: November 2027 · NCT06239116 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: eloralintide's landscape · RM-718's landscape